Barbara Sanavio

Dr. Barbara Sanavio

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2017 in Nature Materials
Verified
Journal Article
Closed access
PDF file
VCValeria Cagno
Valeria Cagno
PAPatrizia Andreozzi
Patrizia Andreozzi
MDMarco D’aLicarnasso
Marco D’aLicarnasso
PSPaulo Jacob Silva
Paulo Jacob Silva
MMMarie Mueller
Marie Mueller
FSFrancesco Stellacci
Francesco Stellacci

18 June 2009 in Nano Letters
Verified
Journal Article
Closed access
FBFouzia Bano
Fouzia Bano
LFLjiljana Fruk
Ljiljana Fruk
BSBarbara Sanavio
Barbara Sanavio
MGMaximilian Glettenberg
Maximilian Glettenberg
LCLoredana Casalis
Loredana Casalis
GSGiacinto Scoles
Giacinto Scoles

23 March 2019 in Cells
Verified
Journal Article
Open access
PDF file
SMstefania marcuzzo
stefania marcuzzo
DIDavide Isaia
Davide Isaia
SBSilvia Bonanno
Silvia Bonanno
CMClaudia Malacarne
Claudia Malacarne
Paola CavalcantePaola Cavalcante
Paola Cavalcante
PBPia Bernasconi
Pia Bernasconi
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motor neurons. In ALS mice, neurodegeneration is associated with the proliferative restorative attempts of ependymal stem progenitor cells (epSPCs) that normally lie in a quiescent in the spinal cord. Thus, modulation of the proliferation of epSPCs may represent a potential strategy to counteract neurodegeneration. Recent studies demonstrated that FM19G11, a hypoxia-inducible factor modulator, induces epSPC self-renewal and proliferation. The aim of the study was to investigate whether FM19G11-loaded gold nanoparticles (NPs) can affect self-renewal and proliferation processes in epSPCs isolated from G93A-SOD1 mice at disease onset. We discovered elevated levels of SOX2, OCT4, AKT1, and AKT3, key genes associated with pluripotency, self-renewal, and proliferation, in G93A-SOD1 epSPCs at the transcriptional and protein levels after treatment with FM19G11-loaded NPs. We also observed an increase in the levels of the mitochondrial uncoupling protein (UCP) gene in treated cells. FM19G11-loaded NPs treatment also affected the expression of the cell cycle-related microRNA (miR)-19a, along with its target gene PTEN, in G93A-SOD1 epSPCs. Overall our findings establish the significant impact of FM19G11-loaded NPs on the cellular pathways involved in self-renewal and proliferation in G93A-SOD1 epSPCs, thus providing an impetus to the design of novel tailored approaches to delay ALS disease progression.

26 February 2015 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
BSBarbara Sanavio
Barbara Sanavio
SKSilke Krol
Silke Krol
Recent advancements in point-of-care technologies show great transformative promises for personalized preventative and predictive medicine. However, fields like therapeutic drug monitoring, that first allowed for personalized treatment of patient’ disease, still lag behind in the widespread application of point-of-care devices for monitoring of patients. Surprisingly, very few applications in commonly monitored drugs, such as anti-epileptics, are paving the way for a point of care (PoC) approach to patient’ therapy monitoring, compared to other fields –like intensive care cardiac markers monitoring, glycemic controls in diabetes, or bench-top hematological parameters analysis at the local drug store. Such delay in the development of portable fast clinically effective drug monitoring devices is in our opinion due more to an inertial drag on the pervasiveness of these new devices into the clinical field than a lack of technical capability. At the same time, some very promising technologies failed in the clinical practice for inadequate understanding of the outcome parameters necessary for a relevant technological breakthrough that has superior clinical performance. We hope, by overviewing both therapeutic drug monitoring practice and its yet unmet needs and latest advancement in micro and nanotechnology applications to PoC clinical devices, to help bridging the two communities, the one exploiting analytical technologies and the one mastering the most advanced techniques, into translating existing and forthcoming technologies in effective devices.

28 November 2016 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
FSFernanda Sousa
Fernanda Sousa
BSBarbara Sanavio
Barbara Sanavio
ASAlessandra Saccani
Alessandra Saccani
YTYun Tang
Yun Tang
IZIleana Zucca
Ileana Zucca
SKSilke Krol
Silke Krol

Verified
Journal Article
Open access
PDF file
Alexandre MironovAlexandre Mironov
Alexandre Mironov
AMAnna Mironov
Anna Mironov
BSBarbara Sanavio
Barbara Sanavio
SKSilke Krol
Silke Krol
GBGalina V Beznoussenko
Galina V Beznoussenko
The main component of blood and lymphatic vessels is the endothelium covering their luminal surface. It plays a significant role in many cardiovascular diseases. Tremendous progress has been made in deciphering of molecular mechanisms involved into intracellular transport. However, molecular machines are mostly characterized in vitro. It is important to adapt this knowledge to the situation existing in tissues and organs. Moreover, contradictions have accumulated within the field related to the function of endothelial cells (ECs) and their trans-endothelial pathways. This has induced necessity for the re-evaluation of several mechanisms related to the function of vascular ECs and intracellular transport and transcytosis there. Here, we analyze available data related to intracellular transport within ECs and re-examine several hypotheses about the role of different mechanisms in transcytosis across ECs. We propose a new classification of vascular endothelium and hypotheses related to the functional role of caveolae and mechanisms of lipid transport through ECs.